Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients

Diabetes Care

Volumn 21, Issue 6, 1998, Pages 994-998

  Werle, Egon ^a   Fiehn, Walter ^a   Hasslacher, Christoph ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b StJosefs Krankenhaus Heidelberg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 MICROGLOBULIN; APOLIPOPROTEIN E; CHOLESTEROL; HEMOGLOBIN A1C; IMMUNOGLOBULIN G;

ADULT; ARTICLE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR;

ADULT; ALBUMINURIA; ALPHA-GLOBULINS; ANALYSIS OF VARIANCE; APOLIPOPROTEINS E; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CREATININE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GENOTYPE; GERMANY; HUMANS; IMMUNOGLOBULIN G; KIDNEY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTEASE INHIBITORS; REGRESSION ANALYSIS; RISK FACTORS; TRIGLYCERIDES;

EID: 0031769084     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.6.994     Document Type: Article

References (39)

1. Krolewski AS, Warram JH, Freire MB: Epidemiology of late diabetic complications: a basis for the development and evaluation of preventive programs. In Endocrinology ana Metabolism Clinicians of North America. Brownlee M, King GL, Eds. Philadelphia, PA, WB Saunders, 1996, p. 217-242
2. Koivisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J, IdziorWalus B: Cardiovascular disease and its risk factors in IDDM in Europe: EURODIAB IDDM Complications Study Group. Diabetes Care 19:689-697, 1996
3. Joven J, Vilella E, Costa B, Turner PR, Richart C, Masana L: Concentrations of lipids and apolipoproteins in patients with clinically well-controlled insulin-dependent and non-insulin-dependent diabetes. Gin Chem 35:813-816, 1989
4. Taskinen MR: Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 41 (Suppl. 2): 12-17, 1992
5. American Diabetes Association: Detection and management of lipid disorders in diabetes. Diabetes Care 16:828-834, 1993
6. Georgopoulos A: Are chylomicron remnants involved in the atherogenesis of insulin-dependent diabetes mellitus? J Lab Clin Med 123:640-646, 1994
7. Ruotolo G, Parlavecchia M, Taskinen MR, Galimberti G, Zoppo A, Le NA, Ragogna F, Micossi P, Pozza G: Normalization of lipoprotein composition by intraperitoneal insulin in IDDM: role of increased hepatic lipase activity Diabetes Care 17:6-12, 1994
8. Wade DP, Knight BL, Soutar AK: Hormonal regulation of low-density lipoprotein (LDL) receptor activity in human hepatoma Hep G2 cells: insulin increases LDL receptor activity and diminishes its suppression by exogenous LDL. Eur J Biochem 174:213-218, 1988
9. Streicher R, Kotzka J, Müller-Wieland D, Siemeister G, Munck M, Avci H, Krone W: SREBP-1 mediates activation of the lowdensity lipoprotein receptor promoter by insulin and insulin-like growth factor I. J Biol Chem 271:7128-7133, 1996
10. Nelson JA, Stephen R, Landau ST, Wilson DE, Tyler FH: Intraperitoneal insulin administration produces a positive portalsystemic blood insulin gradient in unanesthetized, unrestrained swine. Metabolism 31:969-972, 1982
11. Georgopoulos A, Saudek CD: Intraperitoneal insulin delivery decreases the levels of chylomicron remnants in patients with IDDM. Diabetes Care 17:1295-1299, 1994
12. Siest G, Pillot T, Regis-Bailly A, LeiningerMuller B, Steinmetz, J, Galteau MM, Visvikis S: Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem 41:1068-1086, 1995
13. Eichner JE, Kuller LH, Orchard TJ, Grandits GA, McCallum LM, Ferrell RE, Neaton JD: Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol 71:160-165, 1993
14. de Andrade M, Thandi I, Brown S, Gotto A Jr, Patsch W, Boerwinkle E: Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis. Am J Hum Genet 56:1379-1390, 1995
15. Mogensen CE, Christensen K, Vittinghus E: The stages in diabetic renal disease with emphasis on the stage of incipient diabetic nephropathy. Diabetes 32:64-78, 1983
16. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J lipid Res 31:545-548, 1990
17. Werle E, Schneider C, Renner M, Völker M, Fiehn W; Convenient single-step, one tube purification of PCR products for direct sequencing. Nucleic Acids Res 22:4354-4355, 1994
18. Kohlmeier M: Simplified lipoprotein analysis with ultracentrifuge. Clin Lab 32:46-52, 1986
19. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. ClinChem 18:499-502, 1972
20. Werle E, Künstler M, Fiehn W: Comparison of three immunonephelometric tests and an elect roimmunodiffusion method for the determination of lipoprotein(a). J Lab Med 21:88-96, 1997
21. Li KM, Wilcken DE, Dudman NP: Effect of serum lipoprotein(a) on estimation of lowdensity lipoprotein cholesterol by the Friedewald formula. Clin Chem 40:571-573, 1994
22. Eggertsen G, Tegelman R, Ericsson S, Angelin B, Berglund L: Apolipoprotein E polymorphism in a healthy Swedish population: variation in allele frequency with age and relation to serum lipid concentrations, Clin Chem 39:2125-2129, 1993
23. Siegel RD, Cupples A, Schaefer EJ, Wilson PW: Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham Offspring Study. Metabolism 45:1267-1272, 1996
24. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP: Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41:715-722, 1992
25. Rader DJ, Mann WA, Cain W, Kraft HG, Usher D, Zech LA, Hoeg JM, Davignon J, Lupien P, Grossman M, Wilson JM, Brewer HB: The low-density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Gin Invest 95:1403-1408, 1995
26. Bommer C, Werle E, Walter-Sack I, Keller C, Gehlen F, Wanner C, Nauck M, März W Wieland H, Bommer J: d-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients. J Am Soc Nephrol 9:90-96, 1998
27. Bagdade JD, Dutin FL, Eckel RH, Ritter MC: Intraperitoneal insulin therapy corrects abnormalities in cholesteryl ester transfer and lipoprotein lipase activities in insulin-dependent diabetes mellitus. Arte- Tiosdcr Thromb 14:1933-1939, 1994
28. Davignon J, Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8:1-21, 1988
29. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM: Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arteriosder Thromb Vase Biol 16:1250-1255, 1996
30. Wenham PR, Sedky A, Spooner RJ: Apolipoprotein E phenotyping: a word of caution. Ann Clin Biochem 28:599-605, 1991
31. Ehnholm C, Lukka M, Kuusi T, Nikkila E, Utermann G: Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res 27:227-235, 1986
32. Ukkola O, Kervinen K, Salmela PI, vonDickhoff K, Laakso M, Kesäniemi YA: Apolipoprotein E phenotype is related to macro- and microangiopathy in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 101:9-15, 1993
33. Boemi M, Sirolla C, Amadio L, Fumelli P, Pometta D, James RW: Apolipoprotein E polymorphism as a risk factor for vascular disease in diabetic patients. Diabetes Care 18:504-508, 1995
34. Eichner JE, Ferrell RE, Kamboh MI, Kuller LH, Becker DJ, Drash AL, Stein EA, Orchard TJ: The impact of the apolipoprotein E polymorphism on the lipoprotein profile in insulin-dependent diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study IX. Metabolism 41:347-351, 1992
35. Onuma T, Laffel LM, Angelico MC, Krolewski AS: Apolipoprotein E genotypes and risk of diabetic nephropathy. J Am Soc Nephroi 7:1075-1078, 1996
36. Coonrod BA, Elite D, Becker DJ, Bunker CH, Kelsey SF, Lloyd CE, Drash AL, Kuller LH, Orchard TJ: Predictors of microalbuminuria in individuals with IDDM: Pittsburgh Epidemiology of Diabetes Complications Study Diabetes Care 16:1376-1383, 1993
37. JovenJ, SimoJM, Vilella E, CampsJ, Espinel E, Villabona C: Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria. Clin Chem 41:908-913, 1995
38. Swami S, Sztalryd C, Kraemer FB: Effects of streptozotocin-induced diabetes on lowdensity lipoprotein receptor expression in rat adipose tissue. J Lipid Res 37:229-236, 1996
39. de Faria E, Fong LG, Komaromy M, Cooper AD: Relative roles of the LDL receptor, the LDL receptor-like protein, and hepatic lipase in chylomicron remnant removal by the liver J Lipid Res 37:197-209, 1996